AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...
Drug
Abbisko Therapeutics Initiates Phase II Study for Pimicotinib in Chronic Graft-Versus-Host Disease
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing...
Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration...
CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
Salubris Pharmaceuticals’ Enarodustat Gains NMPA Approval for Renal Anemia Treatment
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...
Keymed Biosciences’ CM313 Monoclonal Antibody Shows Promise in Phase I Study for Multiple Myeloma
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that the latest results from a Phase...
HutchMed Presents Updated Data on Hematological Malignancy Therapies at EHA and ICML
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that new and updated clinical data...
Reistone Biopharma’s Ivarmacitinib Accepted for Review by China’s CDE for Atopic Dermatitis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
CDE Indicates Priority Review for Overland ADCT’s Zynlonta and BeiGene’s Brukinsa
The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)...
NMPA Approves Betta Pharmaceuticals’ Vorolanib for Second-Line RCC Treatment in Combination with Everolimus
The National Medical Products Administration (NMPA) has granted approval for Betta Pharmaceuticals Co., Ltd’s (SHE:...
Zelgen Biopharmaceuticals’ ZGGS15 Earns FDA Approval for Advanced Solid Tumor Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...
Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...
CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM
Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...